| Literature DB >> 26956713 |
Jolanda I Kamstra1, Harry Reintsema2, Jan L N Roodenburg2, Pieter U Dijkstra2,3.
Abstract
PURPOSE: The Dynasplint Trismus System (DTS) can be used to treat trismus secondary to head and neck cancer. We conducted a prospective study with the following aims: (1) to determine the effects of DTS exercises on changes in mouth opening, pain, mandibular function, quality of life (QoL), and symptomatology and (2) to analyze the patients' perception on DTS exercises, including user satisfaction, experiences, comfort, and compliance.Entities:
Keywords: Dynasplint Trismus System; Exercise therapy; Head and neck neoplasms; Physical therapy modalities; Trismus
Mesh:
Year: 2016 PMID: 26956713 PMCID: PMC4917584 DOI: 10.1007/s00520-016-3131-4
Source DB: PubMed Journal: Support Care Cancer ISSN: 0941-4355 Impact factor: 3.603
Patient, tumor, and treatment characteristics
| Variable |
|
|---|---|
| Patient characteristics | |
| Male | 9 (50) |
| Age at baseline (years), mean (sd) | 62.1 (12.7) |
| Deceased | 1 (6) |
| Dental state | |
| Dentulous | 10 (56) |
| Partially edentulous | 4 (22) |
| Edentulous | 4 (22) |
| Previous exercise therapy | 5 (28) |
| Interval between primary tumor treatment and start of DTS exercise program (months), median (IQR) | 18.4 (12.4; 54.8) |
| Group ≤36, median (IQR) | 13.9 (7.3–19.0) |
| Group >36, median (IQR) | 110.3 (44.1; 236.6) |
| Tumor characteristics | |
| Squamous cell carcinoma | 14 (78) |
| Location of the primary tumorb | |
| Oral cavity | 9 (50) |
| Pharynx (oropharynx, nasopharynx, hypopharynx) | 7 (39) |
| Maxillary sinus | 1 (6) |
| Skin (region ear) | 1 (6) |
| Stage T4 | 7 (39) |
| Treatment characteristics primary tumorc | |
| Photodynamic therapy | 1 (6) |
| Surgery | 11 (61) |
| Neck dissection | 10 (56) |
| Radiotherapy | 14 (78) |
| Dose radiation on primary tumor, mean (sd) | 65.3 (5.1) |
| Chemotherapy | 5 (28) |
IQR interquartile range
a N (%) unless mentioned otherwise subsequent to the variable
bSome patients underwent a combination of treatment modalities
cExceeds 100 % due to rounding
Fig. 1Group <36 (patients A until L, interval between primary tumor treatment and start of the DTS exercise program less than 36 months): gray shades. Group >36 (patients M till R, interval between primary tumor treatment and start of the DTS exercise program more than 36 months): pink shades. Asterisk, end of the DTS exercise program
Mouth opening, pain, mandibular function, QoL, and symptomatology
| Baseline ( | End of DTS exercise program ( | Follow-up ( | Significance (Friedman) | Baseline vs. end of DTS exercise program ( | Baseline vs. follow-up ( | |
|---|---|---|---|---|---|---|
| Mean (sd) | Mean (sd) | Mean (sd) | Mean (sd) | Mean (sd) | ||
| Mouth opening (mm) | 22.6 (7.6) | 29.7 (10.8) | 27.8 (8.3) | <0.001* | 7.1 (4.7) | 5.0 (3.2) |
| Group ≤36 | 24.0 (6.8) | 30.6 (9.4) | 29.0 (5.3) | 0.001* | 7.3 (4.7) | 5.3 (3.5) |
| Group >36 | 19.7 (8.8) | 27.3 (15.4) | 25.3 (13.1) | 0.057 | 6.5 (5.2) | 4.5 (3.1) |
| Pain at rest (VAS score 0–100 points) | 1.7 (5.0) | 2.3 (6.7) | 5.2 (11.1) | 0.584 | 0.9 (8.5) | 3.5 (12.1) |
| Pain at maximal mouth opening (VAS score 0–100 points) | 21.8 (19.3) | 11.9 (13.8) | 24.8 (21.9) | 0.042* | −6.1 (15.5) | 3.1 (15.5) |
| MFIQ score (0–68 points) | 28.8 (15.3) | 24.1 (14.8) | 22.7 (11.7) | 0.920 | −2.8 (13.3) | −2.0 (10.1) |
| EORTC QLQ-C30 scores (0–100 points) | ||||||
| Global health status (QoL) | 75.5 (21.9) | 81.1 (17.4) | 86.8 (15.3) | 0.141 | 0.0 (11.4) | 6.9 (11.1) |
| Symptomatology overall | 13.1 (15.6) | 10.3 (11.8) | 9.4 (13.7) | 0.779 | −0.7 (10.8) | 0.4 (11.9) |
| EORTC QLQ-H&N35 scores (0–100 points) | ||||||
| Symptomatology overall | 22.9 (15.8) | 17.5 (13.4) | 13.1 (9.6) | 0.086 | −1.9 (8.3) | −5.4 (9.1) |
| Perceived difficulty of opening the mouth | 83.3 (20.6) | 60.0 (31.4) | 58.3 (32.2) | 0.006* | −20.0 (24.6) | −22.2 (29.6) |
*Significant (p < 0.05)
Independent variables related to change in mouth opening
| Baseline vs. end of exercises ( | Baseline vs. follow-up ( | |||||||
|---|---|---|---|---|---|---|---|---|
| Correlation coefficient | Mean (sd) | Significance | Test | Correlation coefficient | Mean (sd) | Significance | Test | |
| Initial mouth opening (mm) | 0.494 | 0.061 | Spearman | −0.021 | 0.948 | Spearman | ||
| Time from treatment of primary tumor to start of exercises (months) | −0.085 | 0.763 | Spearman | 0.081 | 0.802 | Spearman | ||
| Group | 0.694 | MWU | 1.000 | MWU | ||||
| 1 | 7.3 (4.7) | 5.2 (3.5) | ||||||
| 2 | 6.5 (5.2) | 4.5 (3.1) | ||||||
| Stage T4 | 0.044* | MWU | 0.213 | MWU | ||||
| Yes | 5.2 (4.1) | 7.3 (2.6) | ||||||
| No | 10.7 (3.7) | 4.4 (2.4) | ||||||
Spearman Spearman’s correlation coefficient, MWU Mann-Whitney U
*Significant (p < 0.05)
Active lateral exercises
| Baseline ( | End of DTS exercise program ( | Follow-up ( | |
|---|---|---|---|
| Mean (sd) | Mean (sd) | Mean (sd) | |
| Left active lateral exercises of the mandible (mm) | 5.4 (3.0) | 6.4 (3.0) | 6.8 (3.5) |
| Right active lateral exercises of the mandible (mm) | 4.4 (2.7) | 5.5 (3.3) | 5.5 (3.1) |